HCM - Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development
- Insilico Medicine, a Hong Kong company devoted to using AI to speed up drug discovery and R&D, closed a $255 million Series C round led by Warburg Pincus.
- Jointech, a Hangzhou medical device company, has raised $62 million over the last 15 months to support its orthopedic surgery robot business.
- BeiGene, a Beijing biotech, reported its anti-PD-1 antibody tislelizumab has been approved in China for two new indications, bringing the total to five.
- HUTCHMED and AstraZeneca report their MET tyrosine kinase inhibitor was granted conditional China approval for patients with a rare form of NSCLC.
For further details see:
Week In Review: Insilico Closes $255 Million Round For AI Drug Discovery/Development